[Skip to Content]
[Skip to Content Landing]
Correspondence
October 20, 2008

Recurrent Hyperglycemia During Adalimumab Treatment in a Patient With Psoriasis

Arch Dermatol. 2008;144(10):1403-1404. doi:10.1001/archderm.144.10.1403

Tumor necrosis factor (TNF) inhibitors are increasingly used in psoriasis treatment. We describe a patient with psoriasis and diabetes mellitus (DM) who developed recurrent hyperglycemia during adalimumab treatment.

The patient presented in 1999 at age 31 years with a 4-year history of psoriasis and psoriatic spondylarthritis. Different systemic treatments, including UV-B, efalizumab, cyclosporine, and acitretin were tried but were discontinued owing either to toxic effects or lack of efficacy. Photochemotherapy proved most effective, but the patient discontinued therapy owing to its inconvenience.

×